Research Desk Line-up: Kite Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 21, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=JAZZ. The Company announced on August 18, 2017, that Jazz Investments I Ltd, its wholly owned subsidiary, has offered 1.50% exchangeable senior notes due 2024 for an aggregate principal amount of $500 million. Jazz Investments I Ltd offered the notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Kite Pharma, Inc. (NASDAQ: KITE) for due-diligence and potential coverage as the Company reported on August 08, 2017, its financial results for Q2 2017 and also provided a corporate update for the period which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Kite Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JAZZ; also brushing on KITE. Go directly to your stock of interest and access today's free coverage at:
Details About the Offer
- The Issuer has provided a 13-day option to purchase up to an additional $75 million aggregate principal amount of notes to the initial purchasers of the notes.
- It is anticipated that the sale of notes will close on August 23, 2017, subject to certain customary closing conditions.
- An important point to note is that Jazz Pharmaceuticals will fully and unconditionally guarantee the issuer's obligations under the notes on a senior unsecured basis. In fact, it will rank pari passu in right of payment with the Issuer's existing 1.875% exchangeable senior notes due 2021.
Proceeds to Be Used to Repay Outstanding Borrowings
- Jazz Pharmaceuticals plans to utilize the net proceeds from this offering to fully or partially repay its outstanding borrowings of $500 million under its revolving credit facility.
- Remaining proceeds, if any, will be used for the usual corporate purposes, such as business development activities.
Interest Payments and Maturity
- The interest on these notes will be payable semi-annually in cash in arrears on February 15 and August 15 each year at a rate of 1.50% per year. The interest payments would commence on February 15, 2018.
- The notes will mature on August 15, 2024, unless they are exchanged, repurchased, or redeemed on an earlier date.
Terms and Conditions for Exchange
- Before May 15, 2024, the notes will be exchangeable only after the fulfillment of certain conditions and during certain periods. Post that, they will be exchangeable at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
- The notes will be exchangeable for cash, ordinary shares of Jazz Pharmaceuticals, or a combination of cash and ordinary shares, as per the Issuer's choice.
- The initial exchange rate has been decided at 4.5659 ordinary shares per $1,000 principal amount of notes (equivalent to an initial exchange price of $219.02 per ordinary share, which is around 50% premium over the closing price per ordinary share of $146.01 as on August 17, 2017). This price is, however, subject to adjustment in some events but not for any accrued and unpaid interest.
- None of the notes, the guarantee, or the ordinary shares issuable upon exchange of the notes, if any, has been registered under the Securities Act or the securities laws of any other jurisdiction. In fact, these securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Conditions for Redemption
- The Issuer could redeem the notes on or after August 20, 2021, in whole or in part, upon satisfaction of certain conditions. The redemption can be done at any time prior to maturity once all tax-related conditions are satisfied.
- However, the holders of the notes will have the right to demand the issuer to repurchase all or a portion of their notes for cash in the event Jazz Pharmaceuticals undergoes certain fundamental changes.
- Moreover, in case some make-whole fundamental changes occur prior to the maturity date of the notes or upon the Issuer's issuance of a notice of redemption, the Issuer will have to increase the exchange rate for holders of the notes who choose to exchange their notes due to that make-whole fundamental change, or during the related redemption period.
Last Close Stock Review
On Friday, August 18, 2017, the stock closed the trading session at $144.40, dropping 1.10% from its previous closing price of $146.01. A total volume of 1.60 million shares have exchanged hands, which was higher than the 3-month average volume of 457.75 thousand shares. Jazz Pharma's stock price advanced 5.26% in the past six months and 5.92% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have soared 32.44%. The stock is trading at a PE ratio of 21.99 and currently has a market cap of $8.77 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact-checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.